December 8, 2021: On Monday, The World Health Organization issued a strong recommendation against administering convalescent plasma to treat Covid-19 patients, citing research that shows no improvement in patients who received the treatment.
In convalescent plasma therapy, blood plasma is donated by someone who has recovered from the virus and transferred into a patient battling the virus. The hope the donor’s antibodies help fight the infection.
However, the WHO’s guideline development group found that “there was no clear benefit for critical outcomes such as mortality and mechanical ventilation for patients with non-severe, severe or critical illness, and significant resource requirements in terms of cost and time for the administration.”
The group said the treatment also faces practical challenges, such as finding and testing donors and collecting, storing, and transporting the plasma.
The recommendation is based on 16 trials with more than 16,000 non-severe, severe and critical Covid infections. The group said research on the treatment should proceed in randomized control trials. The new recommendation is published in the British Medical Journal.
IN FEBRUARY, the U.S. Food and Drug Administration scaled back its convalescent plasma emergency use authorization to cover only hospitalized patients early in disease progression and those hospitalized who have immune system disorders in which they cannot produce a strong antibody response.
“Plasma with low levels of antibodies is not helpful in COVID-19,” the FDA said in its revised emergency authorization in February.
The agency issued its original, broader authorization on an emergency basis in the U.S. for all hospitalized patients in August 2020 when there were no other approved treatments for the virus. During the Trump administration, Health and Human Services Secretary Alex Azar had celebrated the use of convalescent plasma as a “milestone achievement” in the efforts to fight Covid.
Since then, the FDA has authorized two Covid treatments: Gilead’s antiviral drug redeliver in October 2020 and Regeneron’s antibody cocktail the following month. Pfizer’s two-dose vaccine was approved about a year ago.
In August, the National Institutes of Health also said convalescent plasma didn’t help patients in an NIH-backed study of more than 500 adult Covid patients at the University of Pittsburgh. The NIH said that the trial was stopped in February due to its lack of effectiveness.
The New England Journal of Medicine, in a study published last month, found that convalescent plasma did not prevent disease progression in high-risk outpatients when administered one week after symptom onset. According to the survey, it also did not improve clinical outcomes in hospitalized patients late in the course of their illness.
However, the study found that convalescent plasma did reduce disease progression in older, outpatient adults if administered within 72 hours of symptom onset.
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
AspenTech, a Massachusetts-based company, plays a pivotal role in the oil and gas industry by leveraging cutting-edge technologies, including AI (artificial intelligence). Let’s delve into how AspenTech contributes to this dynamic sector
It’s no secret that oil and gas is a boom-and-bust industry. Production is currently up, projected to increase to 13.7 million barrels daily in 2024. But this won’t last forever. Whether production is up or down, the key to maximizing production, optimizing efficiency, and taking advantage of increased profits is innovation, digital transformation,and automation.For stakeholders looking to deliver safer, more efficient, and cheaper energy, innovation and automation must be a top priority. Those who fall behind in the race to innovate, ultimately, run the risk of losing market share.
Talking to Thomas Hundertmark, a senior partner in McKinsey’s Houston office, Darren Woods is chairman and CEO of ExxonMobil made some crucial points and also gave some insights on what the conglomerate was doing in order to save the climate.
Today oil and gas producers face severe regulatory and public relations obstacles due to the concern with greenhouse gases and resource depletion. Calgary-based start-up, Advanced Upstream (“AU”), has been disrupting the oil and gas industry with simple and reliable innovative technologies. AU’s products help the oil and gas producers to enhance energy production while reducing the corresponding environmental impact. By decreasing personnel and time on site, and lowering overall HSE risks across the board, the clients can see a notable improvement in their ESG rating, contributing to their bottom line.
Jasmin Staiblin, Chief Executive Officer of ABB Switzerland, says, “Global energy consumption continues to grow and, if left unabated, will lead to an ever-greater risk of irreversibly changing our climate. To take advantage of more sustainable energy sources, the energy landscape is in a state of profound change to allow the integration of increasing amounts of renewable energy sources into the grid, to allow infrastructure to run more intelligently and efficiently, and to ensure the supply of energy is available at all times.
The activation of the Fallon Two Rock solar farm project has recently bolstered the Californian energy …